139 related articles for article (PubMed ID: 38346605)
1. Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.
Samia S; Sandeep Chary P; Khan O; Kumar Mehra N
Int J Pharm; 2024 Mar; 653():123889. PubMed ID: 38346605
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
Leung LK; Wang TT
Breast Cancer Res Treat; 1999 May; 55(1):73-83. PubMed ID: 10472781
[TBL] [Abstract][Full Text] [Related]
3. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy.
Gibson LF; Fortney J; Magro G; Ericson SG; Lynch JP; Landreth KS
Breast Cancer Res Treat; 1999 May; 55(2):107-17. PubMed ID: 10481938
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro.
Suzuki K; Kazui T; Yoshida M; Uno T; Kobayashi T; Kimura T; Yoshida T; Sugimura H
Jpn J Clin Oncol; 1999 Jul; 29(7):323-31. PubMed ID: 10470656
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of apoptosis regulators in breast cancer.
Krajewski S; Krajewska M; Turner BC; Pratt C; Howard B; Zapata JM; Frenkel V; Robertson S; Ionov Y; Yamamoto H; Perucho M; Takayama S; Reed JC
Endocr Relat Cancer; 1999 Mar; 6(1):29-40. PubMed ID: 10732784
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation.
Schmitt E; Sané AT; Steyaert A; Cimoli G; Bertrand R
Biochem Cell Biol; 1997; 75(4):301-14. PubMed ID: 9493953
[TBL] [Abstract][Full Text] [Related]
7. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
8. B-cell lymphoma-2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy.
Gong Q; Wang H; Zhou M; Zhou L; Wang R; Li Y
Med Res Rev; 2024 Mar; 44(2):707-737. PubMed ID: 37983840
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
[TBL] [Abstract][Full Text] [Related]
10. The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.
Yao Q; Chen J; Lv Y; Wang T; Zhang J; Fan J; Wang L
Tumour Biol; 2011 Dec; 32(6):1163-71. PubMed ID: 21861179
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Int J Cancer; 1996 Sep; 67(5):608-14. PubMed ID: 8782646
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
Miller AV; Hicks MA; Nakajima W; Richardson AC; Windle JJ; Harada H
PLoS One; 2013; 8(4):e60685. PubMed ID: 23577147
[TBL] [Abstract][Full Text] [Related]
13. Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance.
Zeng C; Ke Z; Song Y; Yao Y; Hu X; Zhang M; Li H; Yin J
Exp Mol Pathol; 2013 Aug; 95(1):23-31. PubMed ID: 23631820
[TBL] [Abstract][Full Text] [Related]
14. DNAi-peptide nanohybrid smart particles target BCL-2 oncogene and induce apoptosis in breast cancer cells.
Alipour M; Sheikhnejad R; Fouani MH; Bardania H; Hosseinkhani S
Biomed Pharmacother; 2023 Oct; 166():115299. PubMed ID: 37573657
[TBL] [Abstract][Full Text] [Related]
15. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer.
Kandhavelu J; Subramanian K; Naidoo V; Sebastianelli G; Doan P; Konda Mani S; Yapislar H; Haciosmanoglu E; Arslan L; Ozer S; Thiyagarajan R; Candeias NR; Penny C; Kandhavelu M; Murugesan A
Br J Pharmacol; 2024 Jan; 181(1):107-124. PubMed ID: 37183661
[TBL] [Abstract][Full Text] [Related]
16. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
17. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Al-Katib AM
Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132
[TBL] [Abstract][Full Text] [Related]
18. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
19. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
20. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
